Phase IV Studies Need Greater Input From FDA, Industry Tells IoM Panel
Executive Summary
Drug manufacturers need more clarity from FDA regarding post-marketing studies, industry representatives told the Institute of Medicine's Committee on the Assessment of the U.S. Drug Safety System
You may also be interested in...
Drug Safety Issues Require “Courage” From Advisory Cmtes, Nissen Says
Advisory committees should be strengthened to better scrutinize safety data and improve advice given to FDA, Steve Nissen (Cleveland Clinic Foundation) said at the Jan. 17 meeting of the Institute of Medicine's Committee on the Assessment of the U.S. Drug Safety System